Advertisement

Drug Safety

, Volume 11, Issue 3, pp 163–178 | Cite as

The Risks and Benefits of Corticosteroids in Advanced Cancer

  • Robert Twycross
Review Articles Risk-Benefit Assessment

Summary

Corticosteroids are extensively prescribed in advanced cancer for various specific indications (e.g. spinal cord compression), for pain relief, as hormone therapy and to stimulate appetite and wellbeing. Choice of corticosteroid is dictated largely by local fashion, and times of administration are more traditional than pharmacological.

Corticosteroids have many potential disadvantages, some life-threatening (e.g. masked septicaemia). Others are seriously debilitating (e.g. myopathy, avascular bone necrosis). Oropharyngeal candidiasis is a common complication. Corticosteroids are withdrawn in about 5% of patients because of unacceptable adverse effects, including moon-face and diabetes mellitus. Corticosteroid hypersensitivity occurs, and the succinate salts have been associated with bronchospasm. Steroid pseudorheumatism may occur with high dose therapy or when tailing off after a prolonged course.

Important drug interactions with corticosteroids relate to salt and water retention, and decreased glucose tolerance. Some anticonvulsants cause an increased clearance of corticosteroids and, with dexamethasone, up to a 50% reduction in the anticipated effect.

The benefit of corticosteroids in terms of increased appetite, mood and activity has been demonstrated in several controlled trials. The effect may well be time-limited in most patients. In several studies, corticosteroids have resulted in an analgesic-sparing effect. Some centres use very high doses of dexamethasone in cases of spinal cord compression, although the justification for these is not obvious. Corticosteroids are used to help relieve nerve compression pain and in symptomatic raised intracranial pressure. Corticosteroids are also injected locally into or around bone metastases, particularly ribs and the sacro-iliac joints. Epidural injections are used for patients with troublesome intractable low back pain.

Corticosteroids are now used less often in hypercalcaemia because of poor response rates. More benefit is obtained, however, if high dosages are used, e.g. prednisolone 60 to 80 mg/day. Dexamethasone is widely used as an antiemetic in association with chemotherapy. Some centres use dexamethasone by continuous subcutaneous infusion in selected patients when the oral route is not feasible.

The choice of starting dose of a corticosteroid is largely arbitrary. It is important, however, not to miss a possible treatment benefit by prescribing too low a dose. For most patients, an initial dosage of prednisolone of 30 to 60 mg/day (dexamethasone 4 to 8 mg/day) is appropriate. In patients with anorexia, there are several alternative options that should be considered.

There is evidence to suggest that patients with advanced cancer receiving a corticosteroid are not as closely monitored as other patients. There is a need to state clearly in writing the reason(s) for prescription and to review after 1 or 2 weeks. If the expected benefit has not occurred, treatment should be stopped.

Keywords

Corticosteroid Dexamethasone Prednisolone Adis International Limited Advanced Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hanks GW, Trueman T, Twycross RG. Corticosteroids in terminal cancer: a prospective analysis of current practice. Postgrad Med J 1983; 59: 702–6PubMedCrossRefGoogle Scholar
  2. 2.
    British National Formulary, No. 26. London: Pharmaceutical Press, 1993: 12-3Google Scholar
  3. 3.
    Walsh D, Avashia J. Glucocorticoids in clinical oncology. Cleve Clin J Med 1992; 59: 505–15PubMedGoogle Scholar
  4. 4.
    Galicich JH, French LA, Melby JC. Use of dexamethasone in the treatment of cerebral edema resulting from tumours and brain surgery. Lancet 1961; 81: 46–53Google Scholar
  5. 5.
    Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumours: diagnosis and treatment. Ann Neurol 1978; 3: 40–51PubMedCrossRefGoogle Scholar
  6. 6.
    Carter RL, Pittam MR, Tanner NSB. Pain and dysphagia in patients with squamous carcinomas of the head and neck: the role of perineural spread. J R Soc Med 1982; 75: 598–606PubMedGoogle Scholar
  7. 7.
    Flombaum CD, Schroy P, Watson R, et al. Treatment of acute obstructive renal failure with high-dose methylprednisolone. Arch Intern Med 1986; 146: 58–61PubMedCrossRefGoogle Scholar
  8. 8.
    Minton MJ, Knight RK, Rubens RD, et al. Corticosteroids for elderly patients with breast cancer. Cancer 1981; 48: 883–7PubMedCrossRefGoogle Scholar
  9. 9.
    Tannock J, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisolone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 17: 590–7Google Scholar
  10. 10.
    Swartz SL, Dluhy RG. Corticosteroids: clinical pharmacology and therapeutic use. Curr Ther 1978; 19: 145–70Google Scholar
  11. 11.
    Gilman AG, Goodman LS, Rail TW, et al., editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 7th ed. London: Pharmaceutical Press, 1985: 1466Google Scholar
  12. 12.
    Grahame-Smith DG, Aronson JK. The Oxford textbook of clinical pharmacology and drug therapy. 2nd ed. Oxford: Oxford University Press, 1992: 585–6Google Scholar
  13. 13.
    Weissman DE, Dufer D, Vogel V, et al. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987; 5: 125–8PubMedCrossRefGoogle Scholar
  14. 14.
    Spector TD, Sambrook PN. Steroid osteoporosis. BMJ 1993; 307: 519–20PubMedCrossRefGoogle Scholar
  15. 15.
    Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735–40PubMedGoogle Scholar
  16. 16.
    Guslando M, Titobello A. Steroid ulcers: a myth revisited. BMJ 1992; 304: 655–6CrossRefGoogle Scholar
  17. 17.
    Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. Pall Med 1994; 8: 222–8CrossRefGoogle Scholar
  18. 18.
    Schell HW. The risk of adrenal corticosteroid therapy in far-advanced cancer. Am J Med Sci 1966; 252: 641–9PubMedCrossRefGoogle Scholar
  19. 19.
    Carson JL, Strom BL, Schinnar R, et al. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med 1991; 91: 223–8PubMedCrossRefGoogle Scholar
  20. 20.
    Henry DA, Johnston A, Dobson A, et al. Fatal peptic ulcer complications and the use of nonsteroidal anti-inflammatory drugs, aspirin, and corticosteroids. BMJ 1987; 295: 1227–9PubMedCrossRefGoogle Scholar
  21. 21.
    Chan ATC, O’Brien MER. Hypersensitivity to dexamethasone. BMJ 1993; 306: 109PubMedCrossRefGoogle Scholar
  22. 22.
    Fulcher DA, Katelaris CH. Anaphylactoid reaction to intravenous hydrocortisone sodium succinate: a case report and literature review. Med J Aust 1991; 154: 210–4PubMedGoogle Scholar
  23. 23.
    Williams WR. Hypersensitivity to dexamethasone. BMJ 1993; 306: 585–6PubMedCrossRefGoogle Scholar
  24. 24.
    Szczeklik A, Nizankowska E, Czerniawska-Mysik G, et al. Hydrocortisone and airflow impairment in aspirin-induced asthma. J Allergy Clin Immunol 1985; 76: 530–6PubMedCrossRefGoogle Scholar
  25. 25.
    Taniguchi M, Sato A. Aspirin-induced asthmatics (AIA) have cross-sensitivity with the steroid succinate esters. Abstract 358. N Engl Reg Allergy Proc 1988; 9: 338Google Scholar
  26. 26.
    Golding DN, Murray SM, Pearce GW, et al. Corticosteroid myopathy. Ann Physiol Med 1961; 5: 171Google Scholar
  27. 27.
    Eideiberg D. Steroid myopathy. In: Rottenberg DA, editor. Neurological complications of cancer treatment. Boston: Butterworth-Heinemann, 1991: 185–91Google Scholar
  28. 28.
    Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis: a controlled clinical trial. Ann Intern Med 1980; 92: 365–9PubMedGoogle Scholar
  29. 29.
    Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985; 76: 234–42PubMedCrossRefGoogle Scholar
  30. 30.
    Askari A, Vignos PJ, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976; 61: 485–91PubMedCrossRefGoogle Scholar
  31. 31.
    Dropcho EJ, Soong S-J. Steroid induced weakness in patients with primary brain tumors. Neurology 1991; 41: 1235–9PubMedCrossRefGoogle Scholar
  32. 32.
    Goldberg AL, Goodman HM. Relationship between cortisone and muscle work in determining muscle size. J Physiol 1969; 200: 667–75PubMedGoogle Scholar
  33. 33.
    Sury MRJ, Russell GN, Heaf DP. Hydrocortisone myopathy. Lancet 1988; 2: 515PubMedCrossRefGoogle Scholar
  34. 34.
    Van Marie W, Woods KL. Acute hydrocortisone myopathy. BMJ 1980; 281: 271–2Google Scholar
  35. 35.
    Ibels LS, Alfrey AC, Huffer WE, et al. Aseptic necrosis of bone following renal transplantation: experience in 194 transplant recipients and review of the literature. Medicine (Baltimore) 1978; 57: 25–45Google Scholar
  36. 36.
    McCluskey J, Gutteridge DH. Avascular necrosis of bone after high doses of dexamethasone during neurosurgery. BMJ 1982; 284: 333–4PubMedCrossRefGoogle Scholar
  37. 37.
    Osteonecrosis caused by combination chemotherapy [editorial]. Lancet 1982; 1: 433-44Google Scholar
  38. 38.
    Thorne JC, Evans WK, Alison RE, et al. Avascular necrosis of bone complicating treatment of malignant lymphoma. Am J Med 1981; 71: 751–8PubMedCrossRefGoogle Scholar
  39. 39.
    Nixon JE. Early diagnosis and treatment of steroid induced avascular necrosis of bone. BMJ 1984; 288: 741–4PubMedCrossRefGoogle Scholar
  40. 40.
    Zizic TM. Avascular necrosis of bone. Curr Opin Rheumatol 1990; 2: 26–37PubMedCrossRefGoogle Scholar
  41. 41.
    Pattrick M, Doherty M. Facial flushing after intra-articular injection of steroid. BMJ 1987; 295: 1380PubMedCrossRefGoogle Scholar
  42. 42.
    Rotstein J, Good RA. Steroid pseudorheumatism. AMA Arch Int Med 1957; 99: 545–55CrossRefGoogle Scholar
  43. 43.
    Greenberg HS, Kim J-H, Posner JB. Epidural spinal cord compression from metastatic tumour: results with a new treatment protocol. Ann Neurol 1979; 8: 361–6CrossRefGoogle Scholar
  44. 44.
    Gambertoglio JG. Corticosteroids and anticonvulsants. Drug Internc News 1983; 12: 55–8Google Scholar
  45. 45.
    Kobberling J, zur Muhlen AV. The influence of diphenylhydantoin and carbamazepine on the circadian rhythm of free urinary corticoids and on the suppressibility of the basal and the ‘impulsive’ activity of dexamethasone. Acta Endocrinol 1973; 72: 308–18PubMedGoogle Scholar
  46. 46.
    Marble A, Weir GC, Selenkow HA, et al. Characteristics of some adrenocorticosteroid preparations. In: Speight T, editor. Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics. 3rd ed. Auckland: Adis Press, 1987: 564Google Scholar
  47. 47.
    Stoll BA. Corticosteroids in therapy of advanced mammary cancer. BMJ 1963; 2: 210–4PubMedCrossRefGoogle Scholar
  48. 48.
    Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69: 751–4PubMedGoogle Scholar
  49. 49.
    Moertel CG, Schutt AJ, Reitemeier RJ, et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607–9PubMedCrossRefGoogle Scholar
  50. 50.
    Needham PR, Daley AG, Lennard RF. Steroids in advanced cancer: a survey of current practice. BMJ 1992; 305: 999–1000PubMedCrossRefGoogle Scholar
  51. 51.
    Pierquin B, Baillet F, Maylin C. Corticotherapie en Cancerologie. Paris: Malaine, 1978Google Scholar
  52. 52.
    Robustelli Della Cuna G, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. Eur J Clin Oncol 1989; 25: 1817–21CrossRefGoogle Scholar
  53. 53.
    Korman B, McKay RJ. Steroids and postoperative analgesia. Anaesth Intensive Care 1985; 13: 395–8PubMedGoogle Scholar
  54. 54.
    Hong D, Byers MR, Oswald RJ. Dexamethasone treatment reduces sensory neuropeptides and nerve sprouting reactions in injured teeth. Pain 1993; 55: 171–81PubMedCrossRefGoogle Scholar
  55. 55.
    Pieretti S, Di Giannuario A, Loizzo A, et al. Dexamethasone prevents epileptiform activity induced by morphine in in vivo and in vitro experiments. J Pharmacol Exper Ther 1992; 263: 830–9Google Scholar
  56. 56.
    McQuay HJ. Pharmacological treatment of neuralgic and neuropathic pain. In: Hanks GW, editor. Cancer surveys. Vol. 7, no. 1. Oxford: Oxford University Press, 1988: 141–59Google Scholar
  57. 57.
    Sjogren P, Jonsson T, Jensen N-H, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93–7PubMedCrossRefGoogle Scholar
  58. 58.
    Rowell NP. Intralesional methylprednisolone for rib metastases: an alternative to radiotherapy? Pall Med 1988; 2: 153–5CrossRefGoogle Scholar
  59. 59.
    Pybus PK. Osteoarthritis: a new neurological method of pain control. Med Hypotheses 1984; 14: 413–22PubMedCrossRefGoogle Scholar
  60. 60.
    Devor M, Govrin-Lippmann R, Raber P. Corticosteroids reduce neuroma hyperexcitability. In: Fields HL, et al., editors. Advances in pain research and therapy, Vol. 9. New York: Raven Press, 1985: 451–5Google Scholar
  61. 61.
    Kirkham SR. The palliation of cerebral tumours with high-dose dexamethasone: a review. Pall Med 1988; 2: 27–33CrossRefGoogle Scholar
  62. 62.
    Beaney RP, Leenders KL, Brooks DJ. Effects of dexamethasone in brain tumour patients. Lancet 1987; 1: 571–2PubMedCrossRefGoogle Scholar
  63. 63.
    Freshney RI, Sherry A, Hassanzadah M, et al. Control of cell proliferation in human glioma by glucocorticoids. Br J Cancer 1980; 41: 857–66PubMedCrossRefGoogle Scholar
  64. 64.
    Pilkington GJ. Steroids and gliomas: experimental and in vitro studies. In: Capildeo R, editor. Steroids in diseases of the central nervous system. Chichester: John Wiley, 1989: 83–7Google Scholar
  65. 65.
    Posner JB, Howieson J, Cvitkovic E. Disappearing spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. Ann Neurol 1977; 2: 409–13PubMedCrossRefGoogle Scholar
  66. 66.
    Renaudin J, Fewer D, Wilson CB, et al. Dose dependency of Decadron in patients with partially excised brain tumours. J Neurosurg 1973; 39: 302–5PubMedCrossRefGoogle Scholar
  67. 67.
    Capildeo R. High-dose methylprednisolone for the treatment of malignant brain tumours. In: Capildeo R, editor. Steroids in diseases of the central nervous system. Chichester: John Wiley, 1989: 103–12Google Scholar
  68. 68.
    Jamous MA. High-dose methylprednisolone for malignant gliomas: safety and side-effects. In: Capildeo R, editor. Steroids in diseases of the central nervous system. Chichester: John Wiley, 1989: 113–22Google Scholar
  69. 69.
    Weissman DE, Janjan NA, Erickson B, et al. Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neurooncol 1991; 11: 235–9PubMedCrossRefGoogle Scholar
  70. 70.
    Coleman RE. Glucocorticoids in cancer therapy. Biotherapy 1992; 4: 37–44PubMedCrossRefGoogle Scholar
  71. 71.
    Mannheimer IH. Hypercalcaemia of breast cancer: management with corticosteroids. Cancer 1965; 18: 679–91PubMedCrossRefGoogle Scholar
  72. 72.
    Percival RC, Yates AJP, Gray RES, et al. Role of glucocorticoids in management of malignant hypercalcaemia. BMJ 1984; 289: 287PubMedCrossRefGoogle Scholar
  73. 73.
    Thalassinos NC, Joplin FG. Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet 1970; 2: 537–9PubMedCrossRefGoogle Scholar
  74. 74.
    Coleman RE, Woll PJ, Miles M, et al. 3-amino 1, 1 hydroxypropyledine bisphosphonate (ADP) for the treatment of bone metastases from breast cancer. Br J Cancer 1988; 58: 621–5PubMedCrossRefGoogle Scholar
  75. 75.
    Morton AR, Cantrill AR, Pillai GV, et al. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988; 297: 772–3PubMedCrossRefGoogle Scholar
  76. 76.
    Gralla RJ. An outline of anti-emetic treatment. Eur J Cancer Clin Oncol 1989; 25: S7–11PubMedGoogle Scholar
  77. 77.
    Grunberg SM. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev 1989; 3: 216–21PubMedCrossRefGoogle Scholar
  78. 78.
    Ondansetron versus dexamethasone for chemotherapy-induced emesis [editorial]. Lancet 1991; 338: 478Google Scholar
  79. 79.
    Sridhar KS, Hussein AM, Hilsenbeck S, et al. Five-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest 1992; 10: 191–9PubMedCrossRefGoogle Scholar
  80. 80.
    Hursti TJ, Fredrikson M, Steineck G, et al. Endogenous Cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. Br J Cancer 1993; 68: 112–4PubMedCrossRefGoogle Scholar
  81. 81.
    Parry H, Martin K. Single-dose IV dexamethasone: an effective anti-emetic in cancer chemotherapy. Cancer Chemother Pharmacol 1991; 28: 231–2PubMedCrossRefGoogle Scholar
  82. 82.
    Bonneterre J, Kerbrat P, Fargeot P, et al. Tetracosactrin vs methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer. Eur J Cancer 1991; 27: 849–52PubMedCrossRefGoogle Scholar
  83. 83.
    Aapro MS, Alberts DS. Dexamethasone as an anti-emetic in patients treated with cisplatin. N Engl J Med 1981; 305: 520PubMedGoogle Scholar
  84. 84.
    Cairnie AB, Leach KE. Dexamethasone: a potent blocker for radiation-induced taste aversion in rats. Pharmacol Biochem Behav 1982; 17: 305–11PubMedCrossRefGoogle Scholar
  85. 85.
    Leslie RA, Shah Y, Thejomayen M, et al. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990; 68: 279–88PubMedCrossRefGoogle Scholar
  86. 86.
    Twycross RG, Guppy D. Prednisolone in terminal breast and bronchogenic cancer. Practitioner 1985; 229: 57–9PubMedGoogle Scholar
  87. 87.
    Wilcox J, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. BMJ 1984; 288: 27Google Scholar
  88. 88.
    Vecht ChJ, Hovestadt A, Verbiest HBC, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumours: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44: 675–80PubMedCrossRefGoogle Scholar
  89. 89.
    Tchekmedyian NS, Tait N, Moody M, et al. Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin Oncol 1986; 13: 37s–43sGoogle Scholar
  90. 90.
    Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82: 1127–32PubMedCrossRefGoogle Scholar
  91. 91.
    Feliu J, Gonzales-Baron M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia: a placebo controlled study. Am J Clin Oncol 1992; 15: 436–40PubMedCrossRefGoogle Scholar
  92. 92.
    Byyny RL. Withdrawal from glucocorticoid therapy. N Engl J Med 1976; 295: 30–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Robert Twycross
    • 1
  1. 1.Churchill HospitalUniversity of Oxford and Sir Michael Sobell HouseOxfordEngland

Personalised recommendations